EJNMMI Research

Table 1 Histopathological assessment of mice treated with DOTA-Miltuximab® or 6Mbq [177Lu]Lu-DOTA-Miltuximab® on days 3, 5, 7 and 27

From: Targeted beta therapy of prostate cancer with ¹⁷⁷Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

	6Mbq [¹⁷⁷Lu]Lu-DOTA-Miltuximab®														DOTA-Miltuximab®
Day	3			5		7			27						27
	Mouse number														Mouse number
Organ	2.2	3.1	5.2	1.1	2.3	1.3	4.4	5.1	1.2	2.1	2.4	4.1	4.2	4.3	1.4	3.2	3.3	3.4	5.3	5.4
Brain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Heart	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lung	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liver
Portal neutrophilic infiltrate	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0
Focal neutrophilic infiltrate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Inflammation, portal	0	0	0	0	0	0	0	0	0	0	0	NT	0	3	0	0	0	0	0	0
Kidneys
Tubular epithelial regeneration, cortex	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
Inflammation, interstitial	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Spleen	0	0	0	0	0	0	0	0	0	0	0	0	0	0	NT	0	0	0	0	0
Small intestine
Focal neutrophilic infiltrate	0	0	0	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
Testes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

NT not tested
0 = no abnormalities, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

Back to article page